Spirocyclic Amide Derivatives Dual Muscarinic Beta2 Agonists
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for pulmonary disorders like COPD and asthma often require co-administration of muscarinic-receptor antagonists and β-adrenoceptor agonists, which can be cumbersome and may not offer optimal efficacy and side-effect profiles, suggesting a need for a single molecule with dual activity.
Innovation Solution
Development of spirocyclic amide derivatives that act as both muscarinic and β2-receptor agonists, potentially providing improved efficacy, side-effect profiles, and patient compliance through a single agent.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If co-administration of muscarinic-receptor antagonists and β-adrenoceptor agonists is used, then efficacy is improved, but treatment complexity and patient compliance deteriorate
Solution Approach 1:
The patent combines two separate therapeutic agents (muscarinic-receptor antagonist and β2-adrenoceptor agonist) into a single dual-action molecule. This merging approach maintains the therapeutic benefits of both agents while simplifying the treatment regimen to a single medication, thereby improving patient compliance without compromising efficacy
Solution Approach 2:
The invention creates a single molecule that performs multiple functions by acting on both muscarinic receptors and β2-adrenoceptors. This multi-functional compound addresses the limitations of single-agent therapies while avoiding the complexity of co-administration, achieving both improved compliance and maintained efficacy
2Reliability
If co-administration of two separate compounds is used, then therapeutic coverage is improved, but formulation complexity deteriorates
Solution Approach 1:
The patent merges two separate compounds into a single dual-action molecule, thereby simplifying the formulation from two separate medications to one. This approach maintains comprehensive therapeutic coverage while reducing formulation complexity, storage requirements, and dosing instructions
3Ease of operation
If single molecule with dual activity is used, then patient compliance is improved, but molecular complexity deteriorates
Solution Approach 1:
The invention designs a single molecule with dual pharmacological activity that can interact with both muscarinic receptors and β2-adrenoceptors. While the molecular structure is more complex than single-agent compounds, this complexity is justified by the significant improvement in patient compliance and the elimination of co-administration requirements
Data Source
Figure 1~2
Figure 3
AI summary
Diazaspiro [5.5] undecane derivatives and related compounds as muscarinic-receptor antagonists and beta-adrenoceptor agonists for the treatment of pulmonary disorders.